



ACMS President Dr. Allison Vidimos Appointed as Expert Consultant to USP Compounding Committee

January 29, 2018

This week, the United States Pharmacopeia (USP) notified the ACMS that its nominee, current President Allison Vidimos, MD, RPh, FACMS, was appointed as an “expert consultant” to its Compounding Expert Committee. In this role, she will advise on a broad array of compounding issues, including those that impact physician-office compounders.

In November 2015, the USP Compounding Expert Committee released proposed revisions to General Chapter <797> *Pharmaceutical Compounding – Sterile Preparations*, eliminating the risk-based approach to compounding and significantly limiting the ability of most physicians to prepare important medicines in their offices. More importantly, federal statute requires the US Food and Drug Administration (FDA) to recognize USP compounding standards, emphasizing their importance.

As a result of ongoing advocacy by the American Medical Association (AMA) and a coalition of physician organizations working to preserve office-based compounding, the USP agreed to seek the advice and guidance of “expert consultants” to provide feedback to the USP Compounding Expert Committee as it continues to revise General Chapter <797>. A second draft is anticipated for comment in September 2018, with the final version slated for release in December 2019.

The ACMS continues to be an active participant in discussions with the USP and FDA to ensure Mohs surgeons can continue delivering high-quality, efficient skin cancer care, which includes preparing “buffered” lidocaine in their offices for use on their patients at the time of Mohs micrographic surgery. The ACMS has also prepared a written statement for tomorrow’s House Energy and Commerce Health Subcommittee hearing titled, “Examining Implementation of the Compounding Quality Act” which will be submitted for the record by Rep. Marsha Blackburn (R-TN-07).